Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Alnylam Pharmaceuticals Stock Price (Quote) NASDAQ:ALNY
$199.67 ( 0.53% ) Monday, 25th Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $174.39 | $212.00 | Monday, 25th Oct 2021 ALNY stock ended at $199.67. This is 0.53% more than the trading day before Friday, 22nd Oct 2021. During the day the stock fluctuated 3.45% from a day low at $195.99 to a day high of $202.75. |
| 90 days | $172.81 | $212.00 | |
| 52 weeks | $119.29 | $212.00 |
Historical Alnylam Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-25 | $198.00 | $202.75 | $195.99 | $199.67 | 398 260 |
| 2021-10-22 | $205.17 | $205.17 | $198.36 | $198.61 | 477 158 |
| 2021-10-21 | $204.46 | $205.29 | $201.86 | $204.33 | 235 394 |
| 2021-10-20 | $208.31 | $208.81 | $203.17 | $203.82 | 279 715 |
| 2021-10-19 | $203.58 | $207.15 | $201.28 | $206.59 | 259 702 |
| 2021-10-18 | $208.86 | $208.86 | $202.30 | $203.90 | 332 464 |
| 2021-10-15 | $210.00 | $210.19 | $207.37 | $208.56 | 404 820 |
| 2021-10-14 | $207.00 | $212.00 | $205.28 | $209.29 | 455 158 |
| 2021-10-13 | $204.00 | $206.28 | $200.80 | $203.89 | 317 423 |
| 2021-10-12 | $206.38 | $206.51 | $202.49 | $203.44 | 402 307 |
| 2021-10-11 | $203.87 | $206.23 | $202.48 | $204.53 | 222 177 |
| 2021-10-08 | $203.45 | $206.84 | $202.07 | $203.70 | 313 556 |
| 2021-10-07 | $201.83 | $204.94 | $198.85 | $202.91 | 307 382 |
| 2021-10-06 | $196.04 | $201.49 | $196.04 | $201.08 | 553 006 |
| 2021-10-05 | $195.34 | $199.69 | $195.25 | $198.35 | 394 777 |
| 2021-10-04 | $195.00 | $198.05 | $193.01 | $195.02 | 606 403 |
| 2021-10-01 | $188.42 | $193.89 | $186.55 | $192.68 | 399 621 |
| 2021-09-30 | $177.84 | $191.41 | $177.84 | $188.81 | 771 544 |
| 2021-09-29 | $178.53 | $182.66 | $177.00 | $177.45 | 388 181 |
| 2021-09-28 | $180.27 | $184.27 | $174.39 | $177.08 | 1 247 166 |
| 2021-09-27 | $187.13 | $194.47 | $181.40 | $193.85 | 797 854 |
| 2021-09-24 | $185.90 | $189.08 | $185.40 | $187.40 | 209 293 |
| 2021-09-23 | $183.49 | $187.75 | $180.65 | $186.95 | 292 592 |
| 2021-09-22 | $185.21 | $185.42 | $181.26 | $182.21 | 1 025 855 |
| 2021-09-21 | $184.54 | $187.10 | $183.69 | $184.15 | 761 254 |
| 2021-09-20 | $187.97 | $188.16 | $181.96 | $183.46 | 572 593 |
| 2021-09-17 | $190.43 | $191.85 | $185.41 | $190.34 | 1 187 034 |
| 2021-09-16 | $189.10 | $191.86 | $185.97 | $190.20 | 320 574 |
| 2021-09-15 | $187.47 | $190.00 | $186.24 | $187.48 | 417 524 |
| 2021-09-14 | $185.32 | $189.87 | $184.71 | $187.97 | 401 741 |
| 2021-09-13 | $190.55 | $190.55 | $183.00 | $185.79 | 495 721 |
| 2021-09-10 | $190.42 | $192.44 | $188.43 | $189.55 | 374 467 |
| 2021-09-09 | $187.00 | $190.16 | $186.91 | $189.60 | 335 476 |
| 2021-09-08 | $186.65 | $188.88 | $184.21 | $186.31 | 320 567 |
| 2021-09-07 | $197.68 | $197.68 | $188.01 | $188.27 | 623 657 |
| 2021-09-03 | $199.67 | $200.42 | $197.36 | $197.46 | 321 032 |
| 2021-09-02 | $198.99 | $202.77 | $197.03 | $200.18 | 540 805 |
| 2021-09-01 | $200.72 | $201.68 | $196.56 | $197.04 | 439 640 |
| 2021-08-31 | $204.45 | $205.69 | $200.33 | $201.43 | 801 353 |
| 2021-08-30 | $204.80 | $208.32 | $203.11 | $203.51 | 467 308 |
| 2021-08-27 | $202.09 | $208.55 | $201.96 | $203.93 | 376 820 |
| 2021-08-26 | $205.07 | $207.25 | $202.38 | $202.39 | 335 778 |
| 2021-08-25 | $201.18 | $205.39 | $198.70 | $204.92 | 365 211 |
| 2021-08-24 | $199.01 | $202.58 | $196.08 | $201.90 | 298 612 |
| 2021-08-23 | $198.72 | $201.49 | $196.60 | $198.40 | 900 069 |
| 2021-08-20 | $198.43 | $201.32 | $196.12 | $197.78 | 973 213 |
| 2021-08-19 | $196.44 | $201.00 | $195.00 | $196.99 | 379 568 |
| 2021-08-18 | $201.77 | $201.77 | $197.51 | $197.53 | 475 072 |
| 2021-08-17 | $195.71 | $202.34 | $193.85 | $200.25 | 578 343 |
| 2021-08-16 | $196.30 | $198.71 | $193.35 | $196.78 | 659 476 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The companys clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
